Show simple item record

dc.contributor.authorBicker, Kevin L.
dc.contributor.authorAnguish, Lynne
dc.contributor.authorChumanevich, Alexander A.
dc.contributor.authorCameron, Michael D.
dc.contributor.authorCui, Xiangli
dc.contributor.authorWitalison, Erin E.
dc.contributor.authorSubramanian, Venkataraman
dc.contributor.authorZhang, Xuesen
dc.contributor.authorChumanevich, Alena P.
dc.contributor.authorHofseth, Lorne J.
dc.contributor.authorCoonrod, Scott A.
dc.contributor.authorThompson, Paul R
dc.date2022-08-11T08:11:00.000
dc.date.accessioned2022-08-23T17:28:10Z
dc.date.available2022-08-23T17:28:10Z
dc.date.issued2012-10-26
dc.date.submitted2015-05-22
dc.identifier.citationACS Med Chem Lett. 2012 Oct 26;3(12):1081-1085. <a href="http://dx.doi.org/10.1021/ml300288d">Link to article on publisher's site</a>
dc.identifier.issn1948-5875 (Linking)
dc.identifier.doi10.1021/ml300288d
dc.identifier.urihttp://hdl.handle.net/20.500.14038/50021
dc.description<p>At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.</p>
dc.description.abstractThe protein arginine deiminases (PADs) are known to play a crucial role in the onset and progression of multiple inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and cancer. However, it is not known how each of the five PAD isozymes contributes to disease pathogenesis. As such, potent, selective, and bioavailable PAD inhibitors will be useful chemical probes to elucidate the specific roles of each isozyme. Since D-amino amino acids often possess enhanced in cellulo stability, and perhaps unique selectivities, we synthesized a series of D-amino acid analogs of our pan-PAD inhibitor Cl-amidine, hypothesizing that this change would provide inhibitors with enhanced pharmacokinetic properties. Herein, we demonstrate that d-Cl-amidine and d-o-F-amidine are potent and highly selective inhibitors of PAD1. The pharmacokinetic properties of d-Cl-amidine were moderately improved over those of l-Cl-amidine, and this compound exhibited similar cell killing in a PAD1 expressing, triple-negative MDA-MB-231 breast cancer cell line. These inhibitors represent an important step in our efforts to develop stable, bioavailable, and highly selective inhibitors for all of the PAD isozymes.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23420624&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572853/
dc.subjectBiochemistry
dc.subjectEnzymes and Coenzymes
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectTherapeutics
dc.titleD-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy.
dc.typeJournal Article
dc.source.journaltitleACS medicinal chemistry letters
dc.source.volume3
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/thompson/31
dc.identifier.contextkey7135693
html.description.abstract<p>The protein arginine deiminases (PADs) are known to play a crucial role in the onset and progression of multiple inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and cancer. However, it is not known how each of the five PAD isozymes contributes to disease pathogenesis. As such, potent, selective, and bioavailable PAD inhibitors will be useful chemical probes to elucidate the specific roles of each isozyme. Since D-amino amino acids often possess enhanced in cellulo stability, and perhaps unique selectivities, we synthesized a series of D-amino acid analogs of our pan-PAD inhibitor Cl-amidine, hypothesizing that this change would provide inhibitors with enhanced pharmacokinetic properties. Herein, we demonstrate that d-Cl-amidine and d-o-F-amidine are potent and highly selective inhibitors of PAD1. The pharmacokinetic properties of d-Cl-amidine were moderately improved over those of l-Cl-amidine, and this compound exhibited similar cell killing in a PAD1 expressing, triple-negative MDA-MB-231 breast cancer cell line. These inhibitors represent an important step in our efforts to develop stable, bioavailable, and highly selective inhibitors for all of the PAD isozymes.</p>
dc.identifier.submissionpaththompson/31
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.source.pages1081-1085


This item appears in the following Collection(s)

Show simple item record